Our people

Thomas Wolter

Thomas Wolter

Our People

Thomas Wolter

Partner, Patent Attorney

Life Sciences


UPC Representative

Our People

Our IP specialists work at all stages of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.

View the team

News & Insights

We want to keep you up to date with developments in the IP world and let you know what we are up to at Mewburn Ellis.

Learn more

Law & Practice Guide

We believe in making it easy for you to find the information that you want – and you can always contact us if you can’t find what you need

Read our law and practice guides

Thomas works primarily in the biopharma sector, mainly with big pharma companies undertaking drug discovery and development. He advises on all stages of a drug’s lifecycle, from initial discovery through clinical trials to regulatory approval. Working closely with in-house IP teams and scientists, he has extensive experience of the prosecution and European opposition and appeal procedures as well as SPCs. Thomas was involved in litigation and/or opposition proceedings concerning dasatinib, nivolumab, ipilimumab, eptinezumab, abatacept, belatacept, crenezumab, etanercept, calcipotriol, levofloxacin, and others.

Areas of Expertise

  • Immunology and immuno-oncology
  • Therapeutic antibodies
  • Fusion proteins
  • Human blood plasma products
  • Iron carbohydrate complexes
  • Production and formulation of biologics
  • Special drug forms, e.g., polymorphs and enantiomers
  • Combination therapies
  • Patent term extension (PTE) and supplementary protection certificates (SPCs)


Thomas works mainly with biopharma companies including large US and European multinationals, SME's and small biotechs.


Thomas has a double Master’s degree in chemistry and biology from Ruhr-Universität Bochum, Germany, and a PhD from Université Louis Pasteur Strasbourg, France.

He qualified as German and European Patent Attorney in 1999. He has practiced at a German patent law firm before joining Mewburn Ellis in 2020.